[Glucagon-like peptide-1 protects INS-1 cells from interleukin-1β-induced damage by inhibiting the nuclear factor-κB pathway.].
OBJECTIVE
To observe the effect of glucagon-like peptide-1 (GLP-1) on interleukin-1β (IL-1β)-induced damage in INS-1 cells and explore its possible mechanisms.


METHODS
INS-1 cells were divided into normal control group, IL-1β group, and GLP-1+IL-1β group with corresponding treatments. The cell viability was determined by MTT assay, the expression of IKKβ mRNA was detected by real-time PCR, and that of the protein p65 was detected by Western blotting.


RESULTS
In comparison with the normal control group, the cells in the IL-1β group showed a significantly decreased viability by 29% (P < 0.01); compared with those in IL-1β group, the cells in GLP-1+IL-1β group exhibited an significant increase in the cell viability by 30% (P < 0.01). In comparison with the normal control group, the cells in IL-1β group showed an significantly increased expression of IKKβ mRNA (1.967 ± 0.091 vs 1 ± 0, P < 0.05); GLP-1 significantly reduced IL-1β-induced increment of IKKβ mRNA expression to 1.287 ± 0.084 (P < 0.05). IL-1β treatment significantly increased NF-κB protein expression as compared to the control level (0.814 ± 0.111 vs 0.396 ± 0.026, P < 0.01), and GLP-1 significantly inhibited such effect (0.622 ± 0.059, P < 0.05).


CONCLUSIONS
GLP-1 inhibits IL-1β-induced β-cell damage probably by inhibiting the NF-κB pathway.
Li
Sheng-jian
SJ
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. sj__li@163.com
Xue
Yao-ming
YM
Li
Jia
J
Zhu
Bo
B
Zhang
Qiao-ling
QL
Chen
Yi-guang
YG
D002460:Cell Line; D002470:Cell Survival; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology*; D006801:Humans; D051550:I-kappa B Kinase / Q000235:genetics / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000473:pathology*; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D020011:Protective Agents / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
D053583:Interleukin-1beta; D016328:NF-kappa B; D020011:Protective Agents; D012333:RNA, Messenger; D052216:Glucagon-Like Peptide 1; C496559:CHUK protein, human; D051550:I-kappa B Kinase